By Professor David Goldstein

Journal articles

Arun SJ; Xu Z; Fiala-Beer E; Phillips P; Goldstein D; Biankin A; Pirola R; Wilson JS; Apte MV, 2011, 'Hepatocyte growth factor: a potential therapeutic target in pancreatic cancer', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-LB-395

Yang JL; DasGupta R; Hopkins A; Luk F; Goldstein D; Crowe P, 2011, 'Significance of IGF-1R and Its signaling pathways in human sarcoma', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-4416

Goldstein D; Gainford MC; Brown C; Tebbutt N; Ackland SP; Van Hazel G; Jefford M; Abdi E; Selva-Nayagam S; Gebski V; Miller D; Shannon J, 2011, 'Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 67, pp. 519 - 525, http://dx.doi.org/10.1007/s00280-010-1351-8

Clarke SJ; Yip S; Brown C; Van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ, 2011, 'Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; Results of a randomised phase II study (DaVINCI) and meta-analysis', European Journal of Cancer, 47, pp. 1826 - 1836, http://dx.doi.org/10.1016/j.ejca.2011.04.024

Zhi J; Major P; Chen E; Burns I; Robinson B; McKendrick J; Rittweger K; Abt M; Goldstein D, 2011, 'A multi-centre, randomised, open-lable study to assess the steady state paramacokinetics of Bevacizumab given with either Xeloda or FOLFOX-4 in patient with metastatic colorectal cancer', Cancer Chemotherapy and Pharmacology, 68, pp. 1199 - 1206

Sjoquist KM; Goldstein D; Bester L; Bester L, 2011, 'A serious complication of selected internal radiation therapy: case report and literature review', Oncologist, 15, pp. 830 - 835

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469

Goldstein D; Gainford M; Brown C; Tebbutt N; Ackland S; Van Hazel GA; Jefford M; Abdi E; Gebski V; Miller D; Shannon JF, 2011, 'Fixed dose rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 16, pp. 519 - 519

Goldstein D; Butow P; Sze M; Mikhail M; Eisenbruch M, 2011, 'Grappling with cultural differences; Communication between oncologists and immigrant cancer patients with and without interpreters', Patient Education and Counseling, 84, pp. 398 - 405

Webber K; Mok K; Bennett BK; Lloyd AR; Friedlander M; Juraskova I; Goldstein D, 2011, 'If I Am in the Mood, I Enjoy It: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer', Oncologist, 16, pp. 1333 - 1344

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248

Webber K; Cooper A; Kleiven H; Yip D; Goldstein D, 2011, 'Management of metastatic renal cell carcinoma in the era of targeted therapies', Internal Medicine Journal, 41, pp. 594 - 605

Park SB; Goldstein D; Lin CS-Y; Krishnan AV; Friedlander M; Kiernan MC, 2011, 'Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 29, pp. e553 - e554e

Luckett T; Goldstein D; Butow PN; Gebski V; Aldridge L; McGrane J; Ng W; King MT, 2011, 'Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis', Lancet Oncology, 12, pp. 1240 - 1248, http://dx.doi.org/10.1016/S1470

Wirth A; Grigg A; Wolf M; Goldstein D; Johnson C; Davis S; Dutu G; Kypreos P; Smith C; Kneebone A; Herzberg M; Joseph D; Catalano J; Roos DE; Stone J; Reynolds J, 2011, 'Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group', Leukemia and Lymphoma, 52, pp. 786 - 795, http://dx.doi.org/10.3109/10428194.2010.547155

Tebbutt N; murphy F; Zannino D; Wilson D; Cummins MM; Abdi E; Strickland A; Lowenthal RM; Marx G; Karapetis C; Shannon JF; Goldstein D; Nayagam SS; Blum R; Chantrill L; Simes RJ; Price T, 2011, 'Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab', Annals of Oncology, 22, pp. 1834 - 1838

Leighl N; Shepherd H; Butow PN; clarke SJ; Mcjannett M; Beale P; Wilken N; Moore M; Chen E; Goldstein D; Horvath LG; Knox J; Krzyzanowska M; Oza AM; Feld R; Hedley D; Xu W; Tattersall MH, 2011, 'Supporting treatment decision-making in advanced cancer: a randomized trial of a decision aid for patients considering chemotherapy in advanced colorectal cancer', Journal of Clinical Oncology, 29, pp. 2077 - 2084, http://dx.doi.org/10.1200/JCO.2010.32.0754

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002

Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; Van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ; Coates A; O'Connell D; Brown C; Hague W; France A; Hicks S; James R; Masson R; O'Connell R; Pike R; Shoulder J; Stevens L; Tunney V; Vachan B; Wong N; Ackland S; Moylan E; Strickland A; Abdi E; Ransom D; Lowenthal R; Marx G; Nayagam SS; Shannon J; Goldstein D; Karapetis C; Blum R; Eek R; Ward R; Pavlakis N; Wilcken N; Burns I; Wyld D; Underhill C; Claringbold P; Liauw W; Clingan P; Jefford M; Horvath L; McKendrick J; Chong G; Boyce A; Cassidy J; Kirsten F; Clarke S; Guo Y; Innes-Rowe J; Smith A; Williams J; Tournier E; Maliepaard S; Vitullo E; Humm G; Nguyen V; Midolo P; Chorlton C; McDonald L; Oliver L; Sjursen AM; Inglis C; Marafioti T; McCourt J; Howard J; Richards A; Provis A; Rundle A; Whatman A; Emmett L; Raymond B; Byrne S; Withers E; Campbell J; Hodgkins C; Szwajcer M; Parker S; Welby S; Page F; Corker M; Wykes R; Goss C; Whitney S; Oates J, 2010, 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study', Journal of Clinical Oncology, 28, pp. 3191 - 3198, http://dx.doi.org/10.1200/JCO.2009.27.7723

Ngan S; Fisher R; Goldstein D; Solomon M; Burmeister B; Ackland SP; Joseph DJ; McClure B; McLachlan S; Mackay J, 2010, 'A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).', Journal of Clinical Oncology, 28, pp. 3509 - 3509, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3509

Webber K; Goldstein D; Bennett BK; Boyle FM; De Souza PL; Wilcken N; Friedlander M; Lloyd AR, 2010, 'Influence of fatigue after breast cancer adjuvant theraphy on health care utilization and percieved needs', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.9047

Tebbutt NC; Kotasek D; Burris HA; Schwartzberg LS; Hurwitz H; Stephenson J; Adewoye H; Sun Y; Ye Y; Goldstein D, 2010, 'Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, 28, pp. 3538 - 3538, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3538

Klumpen H; Eechoute K; Hertzberg MS; Schwarer AA; Goldstein D; Hughes TP; Liddle C; Mathijssen R; Schellens JH; Gurney H, 2010, 'Pharmacogenetic factors predicting the need for a higher dose of imatinib.', Journal of Clinical Oncology, 28, pp. 3098 - 3098, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3098

Chua YJ; Michael M; Zalcberg JR; Hicks RJ; Goldstein D; Liauw W; Price T, 2010, 'Antitumor effect of somatostatin analogs in neuroendocrine tumors', Journal of Clinical Oncology, 28, http://dx.doi.org/10.1200/JCO.2009.26.0612

Lovell MR; Forder PM; Stockler MR; Butow P; Briganti EM; Chye R; Goldstein D; Boyle FM, 2010, 'A randomized controlled trial of a standardized educational intervention for patients with cancer pain', Journal of Pain and Symptom Management, 40, pp. 49 - 59, http://dx.doi.org/10.1016/j.jpainsymman.2009.12.013

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2010, '5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity', Clinical Neurophysiology, 121, pp. e2 - e2, http://dx.doi.org/10.1016/j.clinph.2009.10.025

Goldstein D; Butow PN; Boyle F; Stockler M; Lovell M; Chye R; Forder P; Briganti E, 2010, 'A randomized controlled trial of a standardized educational intervention for patients with cancer pain', Journal of Pain and Symptom Management, 49, pp. 49 - 59

Blinman P; Duric V; Nowak A; Beale P; Clarke SJ; Briscoe K; Boyce A; Goldstein D; Hudson M; Stockler M, 2010, 'Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?', European Journal of Cancer, 46, pp. 1800 - 1807

Neoptolemos J; stocken D; bassi C; Goldstein D, 2010, 'Adjuvant chemotherapy with flurouracil plus folinic acid vs gemcitabine following pancreatic cancer resection:a randomsied trial JAMA 2010', JAMA - Journal of the American Medical Association, 304, pp. 1073 - 1081

Butow PN; Sze M; Dugal-beri P; Mikhail M; Eisenbruch M; Jefford M; Schofield P; Girgis A; king M; Goldstein D, 2010, 'From inside the bubble: Migrants' perceptions of communication with the cancer tea', Supportive Care in Cancer, 19, pp. 281 - 290

Goldstein D; Gill A; Chou A; Vilain R; Clarkson A; Lui M; Jin R; Tobias VH; Samral J; Smith C; Sioson L; Parker N; Smith R; Sywak M; Wyatt S; Robinson B; Eckstein R; Benn D; Clifton-bligh R, 2010, 'Immunohistochemistry for SDHB divides gastrointestinal stromal tumours (GISTs) into two distinct types', American Journal of Surgical Pathology, 34, pp. 636 - 644

Goldstein D; Ackland S; Van Hazel GA; Jefford M; Shannon JF; Gainford M; Brown C; Abdi E; Miller D; Gebski V; Tebbutt N, 2010, 'Optimising the benefit: a phase II trial of Gemcitabine in fixed dose rate infusion combined with Cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology

Goldstein D; Underhill CR; Olver IN; Kosczwara ; Kay F; Franca M, 2010, 'Reaching Further with Online Education? The Development of an Effective Online Program in Palliative Oncology', Journal of Cancer Education, 25, pp. 317 - 323

Wolf M; Kneebone AB; Goldstein D; Joseph D; Wirth A; Grigg A; Johnson C; Davis S, 2010, 'Risk and Response Adapted Therapy for Early Stage Hodgkin Lymphoma: A Prospective Multi-Centre Study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group', Leukemia and Lymphoma, 52, pp. 786 - 795, http://dx.doi.org/10.3109/10428194.2010.547155

Xu ZH; Vonlaufen A; Phillips PA; Fiala-Beer E; Zhang X; Yang L; Biankin AV; Goldstein D; Pirola R; Wilson JS; Apte MV, 2010, 'Role of pancreatic stellate cells in pancreatic cancer metastasis', American Journal of Pathology, 177, pp. 2585 - 2596, http://linkinghub.elsevier.com/retrieve/pii/S0002-9440(10)60308-2

Goldstein D; Harris C; Harris C, 2010, 'Tamoxifen use in retroperitoneal fibrosis, case report and review of the literature', Internal Medicine Journal, 40, pp. e5 - e7

Harris C; Goldstein D, 2010, 'Tamoxifen use in retroperitoneal fibrosis.', Intern Med J, 40, pp. e5 - e7, http://dx.doi.org/10.1111/j.1445-5994.2010.02373.x

Rossleigh MA; Goldstein D, 2010, 'Treatment of Fluorouracil-Refractory Patients with Liver Metastases from Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy', Journal of Clinical Oncology, 27, pp. 4089 - 4095

Xu Z; Phillips PA; Vonlaufen A; Fiala-Beer E; Yang L; Biankin A; Goldstein D; Pirola R; Wilson J; Apte M, 2009, 'Normal Pancreatic Stellate Cells Facilitate Pancreatic Cancer Progression, Exhibit Transendothelial Migration and Accompany Cancer Cells to Distant Metastatic Sites', PANCREAS, 38, pp. 1062 - 1062, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000271225300403&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Neoptolemos J; Büchler M; Stocken DD; Ghaneh P; Smith D; Bassi C; Moore M; Cunningham D; Dervenis C; Goldstein D, 2009, 'ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma', Journal of Clinical Oncology, 27, pp. LBA4505 - LBA4505, http://dx.doi.org/10.1200/jco.2009.27.18s.lba4505

Neoptolemos J; Büchler M; Stocken DD; Ghaneh P; Smith D; Bassi C; Moore M; Cunningham D; Dervenis C; Goldstein D, 2009, 'ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma', Journal of Clinical Oncology, 27, pp. LBA4505 - LBA4505, http://dx.doi.org/10.1200/jco.2009.27.18_suppl.lba4505

Neoptolemos J; Büchler M; Stocken DD; Ghaneh P; Smith D; Bassi C; Moore M; Cunningham D; Dervenis C; Goldstein D, 2009, 'ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma', Journal of Clinical Oncology, 27, pp. LBA4505 - LBA4505, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.lba4505

Goldstein D; van Hazel G; Selva-Nayagam S; Ackland S; Shapiro J; Carroll S; Cummins M; Brown C; Simes RJ; Spry N, 2009, 'GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC).', J Clin Oncol, 27, pp. 4616, http://www.ncbi.nlm.nih.gov/pubmed/27964183

Phillips P; Chow MW; Vonlaufen A; Xu Z; Yang L; Biankin A; Goldstein D; Pirola R; Wilson J; Apte M, 2009, 'Gene expression profiling of human pancreatic stellate cells and their roles in pancreatic cancer progression.', CANCER RESEARCH, 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702804198&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Phillips P; Yang L; Vonlaufen A; Xu Z; Biankin A; Goldstein D; Pirola R; Wilson J; Apte M, 2009, 'Heat shock proteins are induced during pancreatic stellate cell activation in pancreatic cancer', CANCER RESEARCH, 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702804197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee CK; Hadley A; Desilva K; Smith G; Goldstein D, 2009, 'When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis.', World J Surg Oncol, 7, pp. 8, http://dx.doi.org/10.1186/1477-7819-7-8

Yip D; Karapetis C; Strickland A; Steer CB; Goldstein D, 2009, 'WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.', Cochrane database of systematic reviews (Online)

Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC, 2009, 'Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 27, pp. 1243 - 1249

Girgis A; Hansen V; Goldstein D, 2009, 'Are Australian oncology health professionals burning out? A view from the trenches', European Journal of Cancer, 45, pp. 393 - 399

Girgis A; Hansen V; Goldstein D, 2009, 'Are Australian oncology health professionals burning out? A view from the trenches', European Journal of Cancer, 45, pp. 393 - 399

Back to profile page